---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-26-000014"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:09:45.474476+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xencor Q4 net loss narrows to $6.7M; XmAb819 dose expansion advances; Xtend royalty upside $100-120M

## Summary
- Q4 revenue $28.2M (down 47% YoY), full year $125.6M (up 14%). Net loss $6.7M ($0.09/sh) vs $45.6M prior-year Q4.
- Cash $610.8M at Dec 31, 2025; expects $400-430M at end 2026, funding operations through 2028.
- XmAb819 (ENPP3 x CD3) dose expansion open in CRC, NSCLC, pRCC; plan to present data 2H26 for recommended Ph3 dose, pivotal start 2027.
- Xtend U.S. patent to Dec 2028; expects $100-120M aggregate royalty above OMERS cap from Ultomiris sales.

## SEC filing metadata
- accession: 0001326732-26-000014
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673226000014/0001326732-26-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673226000014/xncr-20260225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-26-000014
- JSON: https://secwatch.observer/filing/0001326732-26-000014.json
- Plain text: https://secwatch.observer/filing/0001326732-26-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.